These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8840313)

  • 1. Practical guidelines for effective treatment of the osteodystrophic uraemic syndrome with intravenous calcitriol.
    Cannella G; Moriero E; Rolla D
    Nephrol Dial Transplant; 1996; 11 Suppl 3():50-3. PubMed ID: 8840313
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy.
    Coburn JW
    Kidney Int Suppl; 1990 Sep; 29():S54-61. PubMed ID: 2214548
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulse dose oral calcitriol therapy for renal osteodystrophy: literature review and practice recommendations.
    Dahl NV; Foote EF
    ANNA J; 1997 Oct; 24(5):550-5. PubMed ID: 9392738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dose-comparable study.
    Mazzaferro S; Pasquali M; Ballanti P; Bonucci E; Di Sanza P; Sardella D; Taggi F; Coen G
    Miner Electrolyte Metab; 1994; 20(3):122-9. PubMed ID: 7816000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
    Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
    N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
    Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
    Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propranolol in uraemic osteodystrophy.
    Brancaccio D; Galmozzi C; Casati S; Ponticelli C
    Lancet; 1978 Oct; 2(8096):940. PubMed ID: 81949
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density.
    Türk S; Akbulut M; Yildiz A; Gürbilek M; Gönen S; Tombul Z; Yeksan M
    Nephron; 2002 Feb; 90(2):188-94. PubMed ID: 11818704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous versus oral calcitriol therapy: is there a clinical difference?
    Lantz JP
    Nephrol News Issues; 1992 Sep; 6(9):38-41. PubMed ID: 1407072
    [No Abstract]   [Full Text] [Related]  

  • 10. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol.
    Arora N; Sandroni S; Moles K
    Adv Perit Dial; 1992; 8():62-4. PubMed ID: 1361854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous calcitriol lowers serum calcium concentrations in uraemic patients with severe hyperparathyroidism and hypercalcaemia.
    Hamdy NA; Brown CB; Kanis JA
    Nephrol Dial Transplant; 1989; 4(6):545-8. PubMed ID: 2507976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
    Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
    Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: effect of calcitriol treatment.
    Coen G; Manni M; Addari O; Ballanti P; Pasquali M; Chicca S; Mazzaferro S; Napoletano I; Sardella D; Bonucci E
    Miner Electrolyte Metab; 1995; 21(6):375-82. PubMed ID: 8592480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
    Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
    [No Abstract]   [Full Text] [Related]  

  • 15. Renal osteodystrophy and its treatment.
    Duursma SA; Mees EJ
    Neth J Med; 1973; 16(2):101-7. PubMed ID: 4705764
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent advances in intravenous calcitriol treatment.
    Brancaccio D; Gallieni M
    Curr Opin Nephrol Hypertens; 1994 Jul; 3(4):411-6. PubMed ID: 8076144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Pulse' oral calcitriol in uraemic patients: rapid modification of parathyroid response to calcium.
    Kwan JT; Almond MK; Beer JC; Noonan K; Evans SJ; Cunningham J
    Nephrol Dial Transplant; 1992; 7(8):829-34. PubMed ID: 1325616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological suppression of hyperparathyroidism in patients treated by periodical hemodialysis. Histological, hormonal, biochemical and radiological study].
    Brancaccio D; Faccini JM; Graziani G; Banfi G; Pedoja G; Watson L
    Minerva Nefrol; 1976; 23(2):149-53. PubMed ID: 1087389
    [No Abstract]   [Full Text] [Related]  

  • 20. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.